CA2832355A1 - Computer based system for predicting treatment outcomes - Google Patents
Computer based system for predicting treatment outcomes Download PDFInfo
- Publication number
- CA2832355A1 CA2832355A1 CA2832355A CA2832355A CA2832355A1 CA 2832355 A1 CA2832355 A1 CA 2832355A1 CA 2832355 A CA2832355 A CA 2832355A CA 2832355 A CA2832355 A CA 2832355A CA 2832355 A1 CA2832355 A1 CA 2832355A1
- Authority
- CA
- Canada
- Prior art keywords
- treatment
- benefit
- population
- function
- individuals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 740
- 230000008901 benefit Effects 0.000 claims abstract description 382
- 238000000034 method Methods 0.000 claims abstract description 293
- 239000000090 biomarker Substances 0.000 claims abstract description 145
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 74
- 230000006870 function Effects 0.000 claims description 247
- 230000000694 effects Effects 0.000 claims description 207
- 230000004075 alteration Effects 0.000 claims description 62
- 239000000470 constituent Substances 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 34
- 238000012545 processing Methods 0.000 claims description 30
- 230000031018 biological processes and functions Effects 0.000 claims description 27
- 230000001413 cellular effect Effects 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 13
- 238000004590 computer program Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 abstract description 180
- 229940079593 drug Drugs 0.000 abstract description 143
- 238000009509 drug development Methods 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 90
- 201000010099 disease Diseases 0.000 description 87
- 230000008569 process Effects 0.000 description 43
- 238000011161 development Methods 0.000 description 39
- 230000018109 developmental process Effects 0.000 description 39
- 230000036541 health Effects 0.000 description 38
- 239000003795 chemical substances by application Substances 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 238000011156 evaluation Methods 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 28
- 238000004891 communication Methods 0.000 description 27
- 238000012544 monitoring process Methods 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 19
- 238000009826 distribution Methods 0.000 description 18
- 238000004088 simulation Methods 0.000 description 17
- 208000006011 Stroke Diseases 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 150000002500 ions Chemical class 0.000 description 16
- 230000007246 mechanism Effects 0.000 description 16
- 206010002383 Angina Pectoris Diseases 0.000 description 15
- 241000282412 Homo Species 0.000 description 15
- 230000002596 correlated effect Effects 0.000 description 15
- 229940125681 anticonvulsant agent Drugs 0.000 description 14
- 239000001961 anticonvulsive agent Substances 0.000 description 14
- 230000006399 behavior Effects 0.000 description 14
- 230000003993 interaction Effects 0.000 description 14
- 230000003285 pharmacodynamic effect Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000000699 topical effect Effects 0.000 description 13
- 241000769223 Thenea Species 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 230000002924 anti-infective effect Effects 0.000 description 11
- 229960005475 antiinfective agent Drugs 0.000 description 11
- 230000007321 biological mechanism Effects 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000037361 pathway Effects 0.000 description 10
- 241000283984 Rodentia Species 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000000391 smoking effect Effects 0.000 description 9
- 102000004310 Ion Channels Human genes 0.000 description 8
- 108090000862 Ion Channels Proteins 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000013500 data storage Methods 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 8
- 230000000857 drug effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 108010052164 Sodium Channels Proteins 0.000 description 7
- 102000018674 Sodium Channels Human genes 0.000 description 7
- -1 antifungals Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 230000035487 diastolic blood pressure Effects 0.000 description 7
- 238000007876 drug discovery Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000008238 biochemical pathway Effects 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000010946 mechanistic model Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 229940126601 medicinal product Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000036982 action potential Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000000091 biomarker candidate Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001078 anti-cholinergic effect Effects 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 239000002111 antiemetic agent Substances 0.000 description 4
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 229940125715 antihistaminic agent Drugs 0.000 description 4
- 239000003430 antimalarial agent Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000193 iodinated contrast media Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 150000002960 penicillins Chemical class 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003177 cardiotonic effect Effects 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005094 computer simulation Methods 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- 229940124581 decongestants Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 230000002874 effect on oedema Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000012854 evaluation process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000002288 golgi apparatus Anatomy 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000013178 mathematical model Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000003158 myorelaxant agent Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000002682 anti-psoriatic effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940125688 antiparkinson agent Drugs 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229940030999 antipsoriatics Drugs 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 229940121383 antituberculosis agent Drugs 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 229940125693 central nervous system agent Drugs 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000007620 mathematical function Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229940125702 ophthalmic agent Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003860 topical agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- WFFZGYRTVIPBFN-UHFFFAOYSA-N 3h-indene-1,2-dione Chemical class C1=CC=C2C(=O)C(=O)CC2=C1 WFFZGYRTVIPBFN-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- LCGTWRLJTMHIQZ-UHFFFAOYSA-N 5H-dibenzo[b,f]azepine Chemical compound C1=CC2=CC=CC=C2NC2=CC=CC=C21 LCGTWRLJTMHIQZ-UHFFFAOYSA-N 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 229940124294 CD33 monoclonal antibody Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102000013975 Delayed Rectifier Potassium Channels Human genes 0.000 description 1
- 108010050556 Delayed Rectifier Potassium Channels Proteins 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100020948 Growth hormone receptor Human genes 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010058179 Hypertensive emergency Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010070070 Hypoinsulinaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Chemical class 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 108010004718 Lipoglycopeptides Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 229940124821 NNRTIs Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 229940116211 Vasopressin antagonist Drugs 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229940126675 alternative medicines Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002380 aminotransferase inhibitor Substances 0.000 description 1
- 229940124323 amoebicide Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124286 antibiotics/antineoplastics Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000003409 antileprotic agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940124289 antineoplastic interferon Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003920 antivertigo agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229940082649 blood substitutes and perfusion irrigating solutions Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229940097228 centrally acting antiadrenergic agent Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 229940000033 dermatological agent Drugs 0.000 description 1
- 229940075527 detoxifying agent for antineoplastic treatment Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940055061 drug used in alcohol dependence Drugs 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229940041006 first-generation cephalosporins Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940041010 fourth-generation cephalosporins Drugs 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000028579 gamma-aminobutyric acid uptake involved in synaptic transmission Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003933 gonadotropin antagonist Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002607 heparin antagonist Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229940124299 hormone/antineoplastic Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000035860 hypoinsulinemia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011312 in silico drug discovery Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000003835 ketolide antibiotic agent Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical class CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229940116557 magnetic resonance imaging contrast media Drugs 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940125703 otic agent Drugs 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940079358 peripheral opioid receptor antagonist Drugs 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229940097224 peripherally acting antiadrenergic agent Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 238000005293 physical law Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000004632 predicting treatment efficacy Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000002379 progesterone receptor modulator Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 229940041008 second-generation cephalosporins Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 229940094890 synthetic ovulation stimulants Drugs 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940125712 tocolytic agent Drugs 0.000 description 1
- 239000003675 tocolytic agent Substances 0.000 description 1
- 229940026754 topical antivirals Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229960003853 ultrasound contrast media Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000002432 uterotonic agent Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003038 vasopressin antagonist Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Probability & Statistics with Applications (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32155510P | 2010-04-07 | 2010-04-07 | |
| US61/321,555 | 2010-04-07 | ||
| PCT/EP2011/001759 WO2011124385A1 (en) | 2010-04-07 | 2011-04-05 | Computer based system for predicting treatment outcomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2832355A1 true CA2832355A1 (en) | 2012-10-13 |
Family
ID=44477613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2832355A Abandoned CA2832355A1 (en) | 2010-04-07 | 2011-04-05 | Computer based system for predicting treatment outcomes |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20130041683A1 (OSRAM) |
| EP (1) | EP2556460A1 (OSRAM) |
| JP (1) | JP5970449B2 (OSRAM) |
| CN (1) | CN102822834B (OSRAM) |
| AU (1) | AU2011238099A1 (OSRAM) |
| CA (1) | CA2832355A1 (OSRAM) |
| RU (1) | RU2601197C2 (OSRAM) |
| WO (1) | WO2011124385A1 (OSRAM) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10831863B2 (en) | 2016-03-24 | 2020-11-10 | Fujitsu Limited | System and a method for assessing patient risk using open data and clinician input |
| US10885150B2 (en) | 2016-03-24 | 2021-01-05 | Fujitsu Limited | System and a method for assessing patient treatment risk using open data and clinician input |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12324657B2 (en) | 2007-11-28 | 2025-06-10 | Intervet Inc. | System and method for diagnosis of bovine diseases using auscultation analysis |
| US8635183B1 (en) * | 2010-04-19 | 2014-01-21 | Bridgehealth Medical, Inc. | Method and apparatus to computer-process data to produce, store, and disseminate output related to medical or health information |
| WO2011124385A1 (en) * | 2010-04-07 | 2011-10-13 | Novadiscovery | Computer based system for predicting treatment outcomes |
| US20200027181A1 (en) * | 2010-09-29 | 2020-01-23 | Dacadoo Ag | Automated health data acquisition, processing and communication system and method |
| US20130014061A1 (en) * | 2011-07-06 | 2013-01-10 | Lockheed Martin Corporation | Method and apparatus for time-based opportunity and risk management |
| US8992228B2 (en) * | 2012-06-19 | 2015-03-31 | MediResource Inc. | Automated system for delivery of targeted content based on behavior change models |
| EP3739596B1 (en) * | 2012-06-21 | 2024-04-24 | Battelle Memorial Institute | Clinical predictive analytics system |
| US9830423B2 (en) | 2013-03-13 | 2017-11-28 | Abhishek Biswas | Virtual communication platform for healthcare |
| US11694797B2 (en) | 2012-10-30 | 2023-07-04 | Neil S. Davey | Virtual healthcare communication platform |
| KR102272849B1 (ko) * | 2013-01-17 | 2021-07-02 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 복합 시스템에 대한 입력 파라미터들의 최적화된 조합들의 빠른 식별 |
| WO2014121133A2 (en) * | 2013-02-03 | 2014-08-07 | Genelex Corporation | Systems and methods for quantification and presentation of medical risk arising from unknown factors |
| BR122022005675B1 (pt) * | 2013-02-06 | 2023-05-02 | Geissler Companies, Llc | Métodos para determinar a eficácia de uma droga |
| US9864837B2 (en) * | 2013-02-28 | 2018-01-09 | Accenture Global Services Limited | Clinical quality analytics system with recursive, time sensitive event-based protocol matching |
| WO2014145705A2 (en) | 2013-03-15 | 2014-09-18 | Battelle Memorial Institute | Progression analytics system |
| WO2014194410A1 (en) * | 2013-06-06 | 2014-12-11 | Timeless Technologies (2007) Inc. | Method and system for providing a treatment protocol |
| US9530095B2 (en) | 2013-06-26 | 2016-12-27 | International Business Machines Corporation | Method and system for exploring the associations between drug side-effects and therapeutic indications |
| EP3129507A4 (en) * | 2014-04-10 | 2017-12-06 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder |
| JP6324828B2 (ja) * | 2014-07-07 | 2018-05-16 | 株式会社日立製作所 | 薬効分析システム及び薬効分析方法 |
| US9349178B1 (en) | 2014-11-24 | 2016-05-24 | Siemens Aktiengesellschaft | Synthetic data-driven hemodynamic determination in medical imaging |
| EP3051449A1 (de) * | 2015-01-29 | 2016-08-03 | Bayer Technology Services GmbH | Computerimplementiertes Verfahren zur Erstellung eines Fermentationsmodels |
| WO2016168474A1 (en) * | 2015-04-17 | 2016-10-20 | Heartflow, Inc. | Systems and methods for assessment of tissue function based on vascular disease |
| RU2599350C1 (ru) * | 2015-06-04 | 2016-10-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" | Способ прогнозирования индивидуальной эффективности лечения статинами (варианты) |
| US20170024539A1 (en) * | 2015-07-23 | 2017-01-26 | PrioBio, LLC | Enhancing blood cell estimation |
| US10825557B2 (en) * | 2015-09-04 | 2020-11-03 | Canon Medical Systems Corporation | Medical information processing apparatus |
| US11216478B2 (en) | 2015-10-16 | 2022-01-04 | o9 Solutions, Inc. | Plan model searching |
| US9906551B2 (en) * | 2016-02-09 | 2018-02-27 | International Business Machines Corporation | Forecasting and classifying cyber-attacks using crossover neural embeddings |
| US11039986B2 (en) * | 2016-02-25 | 2021-06-22 | Samsung Electronics Co., Ltd. | Chronotherapeutic dosing of medication and medication regimen adherence |
| EP3457920A4 (en) | 2016-05-18 | 2019-10-16 | Mark D. Noar | METHOD AND SYSTEM FOR PREDICTING SUCCESSFUL TREATMENT PROCEDURES AND RESULTS OF BODILY DISEASE DISEASES BASED ON TISSUE ENERGY ACTIVITY |
| JP6068715B1 (ja) * | 2016-07-06 | 2017-01-25 | 正彦 原 | 介入効果推測システム、介入効果推測方法、及び、介入効果推測システムに用いるプログラム |
| CN112020748B (zh) * | 2017-07-12 | 2024-03-01 | 费森尤斯医疗保健控股公司 | 进行虚拟临床试验的技术 |
| RU2675067C1 (ru) * | 2017-09-18 | 2018-12-14 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени В.А. Алмазова" Министерства здравоохранения Российской Федерации | Способ прогнозирования возобновления клиники ишемической болезни сердца с помощью нейронных сетей у пациентов после эндоваскулярного вмешательства |
| EP3480823A1 (en) * | 2017-11-02 | 2019-05-08 | Koninklijke Philips N.V. | Clinical decision support |
| US11132621B2 (en) | 2017-11-15 | 2021-09-28 | International Business Machines Corporation | Correction of reaction rules databases by active learning |
| US12027271B2 (en) | 2018-05-03 | 2024-07-02 | Hoffmann-La Roche, Inc. | Visualization of biomedical predictions |
| AU2019277199B2 (en) * | 2018-05-31 | 2024-04-04 | Lynne Bilston | Systems, devices and methods for the treatment of oral and pharyngeal disorders |
| US11177028B2 (en) | 2018-12-06 | 2021-11-16 | International Business Machines Corporation | Extraction, representation, and cognitive interpretation of medically relevant evidence |
| US11605469B2 (en) * | 2018-12-13 | 2023-03-14 | International Business Machines Corporation | Cognitive analysis of data using granular review of documents |
| EP3673955A1 (en) * | 2018-12-24 | 2020-07-01 | Koninklijke Philips N.V. | Automated detection of lung conditions for monitoring thoracic patients undergoing external beam radiation therapy |
| CA3132823A1 (en) * | 2019-03-08 | 2020-09-17 | Diane R. Mould | Systems and methods for drug-agnostic patient-specific dosing regimens |
| US10515715B1 (en) | 2019-06-25 | 2019-12-24 | Colgate-Palmolive Company | Systems and methods for evaluating compositions |
| RU2736391C1 (ru) * | 2019-10-11 | 2020-11-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Способ прогноза терапевтической эффективности анксиолитика афобазола у больных с тревожными расстройствами |
| CN111166289B (zh) * | 2020-01-04 | 2023-02-24 | 山东大学齐鲁医院(青岛) | 一种远程内分泌紊乱检测设备 |
| RU2754884C2 (ru) * | 2020-02-03 | 2021-09-08 | Атлас Биомед Груп Лимитед | Определение фенотипа на основе неполных генетических данных |
| US11328796B1 (en) | 2020-02-25 | 2022-05-10 | Vignet Incorporated | Techniques for selecting cohorts for decentralized clinical trials for pharmaceutical research |
| CN111403040A (zh) * | 2020-06-04 | 2020-07-10 | 成都泰盟软件有限公司 | 基于虚拟标准病人的治疗模拟系统 |
| US12230406B2 (en) | 2020-07-13 | 2025-02-18 | Vignet Incorporated | Increasing diversity and engagement in clinical trails through digital tools for health data collection |
| US12380968B2 (en) | 2020-08-18 | 2025-08-05 | International Business Machines Corporation | Multiple chemical programs for an array of chemical reactors with a single array of reactants |
| US11854670B2 (en) * | 2020-08-18 | 2023-12-26 | International Business Machines Corporation | Running multiple experiments simultaneously on an array of chemical reactors |
| US11798652B2 (en) * | 2020-08-24 | 2023-10-24 | Kpn Innovations, Llc. | Method of and system for identifying and ameliorating body degradations |
| WO2022049606A1 (en) * | 2020-09-07 | 2022-03-10 | Theraindx Lifesciences Pvt Ltd | Systems and methods for identification of cell lines, biomarkers, and patients for drug response prediction |
| CN111956367B (zh) * | 2020-09-18 | 2024-09-27 | 上海中医药大学 | 一种治疗脑肿瘤的纳米给药系统 |
| CN112652368B (zh) * | 2020-12-31 | 2024-09-06 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种数据分析的方法及装置 |
| CN112509669A (zh) * | 2021-02-01 | 2021-03-16 | 肾泰网健康科技(南京)有限公司 | 基于ai技术的肾脏病血液透析方案定制方法及系统 |
| US11196656B1 (en) | 2021-02-03 | 2021-12-07 | Vignet Incorporated | Improving diversity in cohorts for health research |
| US11296971B1 (en) | 2021-02-03 | 2022-04-05 | Vignet Incorporated | Managing and adapting monitoring programs |
| US11316941B1 (en) | 2021-02-03 | 2022-04-26 | Vignet Incorporated | Remotely managing and adapting monitoring programs using machine learning predictions |
| US11789837B1 (en) | 2021-02-03 | 2023-10-17 | Vignet Incorporated | Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial |
| US11521714B1 (en) | 2021-02-03 | 2022-12-06 | Vignet Incorporated | Increasing diversity of participants in health research using adaptive methods |
| US11361846B1 (en) | 2021-02-03 | 2022-06-14 | Vignet Incorporated | Systems and methods for customizing monitoring programs involving remote devices |
| JP2022174614A (ja) * | 2021-05-11 | 2022-11-24 | 国立大学法人金沢大学 | プログラム、情報処理装置及び情報処理方法 |
| US20250349435A1 (en) * | 2022-06-02 | 2025-11-13 | Todra Capital Inc. | System, method and apparatus for assessing efficacy of nutraceutical polyphenols utilizing ai |
| CN115270575B (zh) * | 2022-08-05 | 2025-09-05 | 江苏方天电力技术有限公司 | 一种变频凝结水泵结构优化设计方法 |
| CN115359921B (zh) * | 2022-10-20 | 2023-06-27 | 中融云尚科技有限公司 | 一种基于数据分析的医疗信息存储共享系统 |
| US20240419412A1 (en) * | 2023-06-13 | 2024-12-19 | 1370092 Ontario Ltd. | User interface support module and method of use |
| CN117238522B (zh) * | 2023-11-08 | 2024-10-11 | 查理高特(青岛)健康科技有限公司 | 一种非布司他的疗效预测系统、设备及介质 |
| CN117558460B (zh) * | 2024-01-11 | 2024-04-05 | 卓世未来(天津)科技有限公司 | 基于小样本学习和大语言模型的慢性病管理方法及系统 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6983227B1 (en) * | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
| US5860917A (en) * | 1997-01-15 | 1999-01-19 | Chiron Corporation | Method and apparatus for predicting therapeutic outcomes |
| US6315720B1 (en) * | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| JP4284050B2 (ja) * | 2002-09-27 | 2009-06-24 | 株式会社東芝 | 治療法の有効性を予測するためのプログラム、データベース、システム及び方法 |
| AU2003271725A1 (en) * | 2002-10-15 | 2004-05-04 | Novartis Ag | Methods to predict edema as a side effect of drug treatment |
| US20040115647A1 (en) * | 2002-12-12 | 2004-06-17 | Paterson Thomas S. | Apparatus and method for identifying biomarkers using a computer model |
| EP1685512A2 (en) * | 2003-10-07 | 2006-08-02 | Entelos, Inc. | Simulating patient-specific outcomes |
| US20060073496A1 (en) * | 2004-07-20 | 2006-04-06 | O'toole Margot | Methods of identifying patients at risk of developing encephalitis following immunotherapy for Alzheimer's disease |
| NL1027047C2 (nl) * | 2004-09-15 | 2006-03-16 | Roderik Adriaan Kraaijenhagen | Computerinrichting voor het vaststellen van een diagnose. |
| US20100204920A1 (en) * | 2005-04-25 | 2010-08-12 | Caduceus Information Systems Inc. | System for development of individualised treatment regimens |
| RU2322675C1 (ru) * | 2006-11-08 | 2008-04-20 | Андрей Александрович Темнов | Способ прогнозирования устойчивости организма к стрессорному воздействию |
| US20080140371A1 (en) * | 2006-11-15 | 2008-06-12 | General Electric Company | System and method for treating a patient |
| WO2009076551A2 (en) * | 2007-12-12 | 2009-06-18 | The Regents Of The University Of California | Systems and methods for predicting response of biological samples |
| US20090204424A1 (en) * | 2007-12-14 | 2009-08-13 | Elaine Hughes | Method and System for Distributing Information Between Patients, Health Care Providers, Caregivers, and Payors |
| US20090164251A1 (en) * | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Method and apparatus for providing treatment profile management |
| EP2227780A4 (en) * | 2008-03-19 | 2011-08-03 | Existence Genetics Llc | GENETIC ANALYSIS |
| US20110119259A1 (en) * | 2008-04-24 | 2011-05-19 | Trustees Of Boston University | Network biology approach for identifying targets for combination therapies |
| US8224665B2 (en) | 2008-06-26 | 2012-07-17 | Archimedes, Inc. | Estimating healthcare outcomes for individuals |
| CA2736916A1 (en) * | 2008-10-06 | 2010-04-15 | Merck Sharp & Dohme Corp. | Devices and methods for determining a patient's propensity to adhere to a medication prescription |
| US8694300B2 (en) * | 2008-10-31 | 2014-04-08 | Archimedes, Inc. | Individualized ranking of risk of health outcomes |
| US20110105852A1 (en) * | 2009-11-03 | 2011-05-05 | Macdonald Morris | Using data imputation to determine and rank of risks of health outcomes |
| WO2011124385A1 (en) * | 2010-04-07 | 2011-10-13 | Novadiscovery | Computer based system for predicting treatment outcomes |
-
2011
- 2011-04-05 WO PCT/EP2011/001759 patent/WO2011124385A1/en not_active Ceased
- 2011-04-05 CA CA2832355A patent/CA2832355A1/en not_active Abandoned
- 2011-04-05 EP EP11713708A patent/EP2556460A1/en not_active Ceased
- 2011-04-05 US US13/636,737 patent/US20130041683A1/en not_active Abandoned
- 2011-04-05 RU RU2012133279/08A patent/RU2601197C2/ru active
- 2011-04-05 CN CN201180015982.6A patent/CN102822834B/zh active Active
- 2011-04-05 JP JP2013503039A patent/JP5970449B2/ja active Active
- 2011-04-05 AU AU2011238099A patent/AU2011238099A1/en not_active Abandoned
-
2017
- 2017-05-17 US US15/597,661 patent/US20180039726A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10831863B2 (en) | 2016-03-24 | 2020-11-10 | Fujitsu Limited | System and a method for assessing patient risk using open data and clinician input |
| US10885150B2 (en) | 2016-03-24 | 2021-01-05 | Fujitsu Limited | System and a method for assessing patient treatment risk using open data and clinician input |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011124385A1 (en) | 2011-10-13 |
| CN102822834A (zh) | 2012-12-12 |
| CN102822834B (zh) | 2020-09-25 |
| JP5970449B2 (ja) | 2016-08-17 |
| AU2011238099A1 (en) | 2012-11-29 |
| EP2556460A1 (en) | 2013-02-13 |
| RU2012133279A (ru) | 2014-05-20 |
| JP2013524355A (ja) | 2013-06-17 |
| US20180039726A1 (en) | 2018-02-08 |
| RU2601197C2 (ru) | 2016-10-27 |
| US20130041683A1 (en) | 2013-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180039726A1 (en) | Computer based system for predicting treatment outcomes | |
| Yang et al. | DeepIDC: a prediction framework of injectable drug combination based on heterogeneous information and deep learning | |
| US20090150134A1 (en) | Simulating Patient-Specific Outcomes | |
| US20100324874A9 (en) | Simulating patient-specific outcomes | |
| AU2006210430B2 (en) | Method for defining virtual patient populations | |
| KR20170058391A (ko) | 환자 데이터에 기반한 헬스케어 진단 및 치료를 위한 베이지안 인과 관계 네트워크 모델 | |
| Lecluse et al. | National registries of systemic treatment for psoriasis and the European ‘Psonet’initiative | |
| Boissel et al. | Bridging systems medicine and patient needs | |
| CN111081384A (zh) | 一种心血管疾病临床用药指导系统及方法 | |
| Ponnarengan et al. | Data-Driven Healthcare: The Role of Computational Methods in Medical Innovation. | |
| Pollom et al. | A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers | |
| Chen et al. | RareAgents: Advancing Rare Disease Care through LLM-Empowered Multi-disciplinary Team | |
| Wang et al. | From Bench to Bedside: A Review of Clinical Trials in Drug Discovery and Development | |
| CN105787261B (zh) | 一种基于分子指纹图谱快速评估药物不良反应的方法 | |
| Deorankar et al. | Optimizing Healthcare Throughput: The Role of Machine Learning and Data Analytics | |
| Rajendran et al. | The revolution of digital therapeutics (DTx) in the pharmaceutical industry and their quality impacts | |
| Usman et al. | Pharmacometrics and its application in clinical practice | |
| Surmann et al. | Digital Solutions and the Role of AI in Healthcare | |
| Verma | Bioinformatics, healthcare informatics and analytics: an imperative for improved healthcare system | |
| Yingngam | AI in Clinical Trial Design and Patient Recruitment | |
| Chen et al. | Comparative performance of machine learning and conventional scoring systems for neuroprognostication in out-of-hospital cardiac arrest survivors | |
| Eylenbosch et al. | From reactive to predictive: Advancing biologic dosing in dermatology | |
| Vutova et al. | OP13 Impact of Pay-for-Performance Programs on Diabetes Management: A Critical Analysis | |
| Charanya et al. | Novel ML Algorithms for Healthcare: Enhancing Healthcare in the Field of Personalized Treatments, Patient Monitoring, and Robotic Surger | |
| Tam et al. | Predicting Drug Resistance in Cancer Cell Lines Using Machine Learning Approaches |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160324 |
|
| FZDE | Discontinued |
Effective date: 20200831 |